6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5.7B | -$100M | 0.0% | -1.4% | -$8M | — | $17M |
| 2024 | $4.5B | -$290M | 0.0% | -1.2% | -$57M | — | $35M |
| 2023 | $3.9B | $4M | 0.0% | 1.0% | $25M | — | $5M |
| 2022 | $4.8B | $92M | 0.0% | 2.6% | $253M | — | $98M |
| 2021 | $4.7B | $150M | 0.0% | 4.1% | $116M | — | $29M |
| 2020 | $3.4B | $43M | 0.0% | 1.8% | -$22M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.4B | -$36M | 0.0% | -2.0% | -$24M | — | $21M |
| Dec '25 | $1.5B | -$46M | 0.0% | -2.9% | -$9M | — | $17M |
| Sep '25 | $1.4B | -$14M | 0.0% | -0.5% | $9M | — | $25M |
| Jun '25 | $1.4B | -$9M | 0.0% | 0.0% | $9M | — | $18M |
| Mar '25 | $1.4B | -$31M | 0.0% | -2.1% | -$17M | — | $16M |
| Dec '24 | $1.7B | -$25M | 0.0% | -1.4% | -$19M | — | $35M |
| Sep '24 | $1.0B | -$243M | 0.0% | -1.9% | -$18M | — | $55M |
| Jun '24 | $930M | -$7M | 0.0% | 0.0% | -$16M | — | $7M |
| Mar '24 | $913M | -$15M | 0.0% | -1.3% | -$4M | — | $7M |
| Dec '23 | $978M | $2M | 0.0% | 1.4% | $1M | — | $5M |
| Sep '23 | $976M | -$1M | 0.0% | 0.6% | -$14M | — | $104M |
| Jun '23 | $963M | $3M | 0.0% | 1.5% | $8M | — | $124M |
| Mar '23 | $1.0B | $0 | 0.0% | 0.5% | $30M | — | $121M |
| Dec '22 | $1.1B | -$4M | 0.0% | -0.1% | $58M | — | $98M |
| Sep '22 | $1.1B | $13M | 0.0% | 1.3% | $42M | — | $187M |
| Jun '22 | $1.2B | $44M | 0.0% | 4.7% | $62M | — | — |
| Mar '22 | $1.3B | $39M | 0.0% | 3.9% | $91M | — | — |
| Dec '21 | $1.3B | $42M | 0.0% | 4.1% | $27M | — | $29M |
| Sep '21 | $1.2B | $33M | 0.0% | 3.2% | — | — | — |
How the market has priced RXO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Rxo, Inc.'s revenue has grown 11.3% per year. These are computed facts, not advice.
As of FY2025, Rxo, Inc. reported — of total debt against $17M of cash.
In FY2025, gross margin was —, operating margin -1.4%, and net margin -1.7%.
As of Jun '26, Rxo, Inc. traded at a price-to-earnings ratio of about 1244.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.